Casanova, CiroCelli, Bartolome R.de-Torres, Juan P.Martinez-Gonzalez, CristinaCosio, Borja G.Pinto-Plata, Victorde Lucas-Ramos, PilarDivo, MiguelFuster, AntoniaPeces-Barba, GermanCalle-Rubio, MyriamSolanes, IngridAguero, RamonFeu-Collado, NuriaAlfageme, InmaculadaDe Diego, AlfredoRomero, AmparoBalcells, EvaLlunell, AntoniaGaldiz, Juan B.Marin, MargaritaMoreno, AmaliaCabrera, CarlosGolpe, RafaelLacarcel, CeliaSoriano, Joan B.Luis Lopez-Campos, JoseSoler-Cataluna, Juan J.Marin, Jose M.2023-02-122023-02-122017-07-27Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017 Nov 22;50(5):17011620903-1936http://hdl.handle.net/10668/19115The impact of blood eosinophilia in chronic obstructive pulmonary disease (COPD) remains controversial.To evaluate the prevalence and stability of a high level of blood eosinophils (>= 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1) and its relationship to outcomes, we determined blood eosinophils at baseline and over 2 years in 424 COPD patients (forced expiratory volume in 1 s (FEV1) 60% predicted) and 67 smokers without COPD from the CHAIN cohort, and in 308 COPD patients (FEV1 60% predicted) in the BODE cohort. We related eosinophil levels to exacerbations and survival using Cox hazard analysis.In COPD patients, 15.8% in the CHAIN cohort and 12.3% in the BODE cohort had persistently elevated blood eosinophils at all three visits. A significant proportion (43.8%) of patients had counts that oscillated above and below the cut-off points, while the rest had persistent eosinophil levels = 300 cells.mu L-1 persisting over 2 years was not a risk factor for COPD exacerbations. High eosinophil count was associated with better survival.enObstructive pulmonary-diseaseClinical characteristicsInhaled corticosteroidsExacerbationsAsthmaFluticasoneGuidelinesBiomarkerEfficacyDyspneaEosinophilsForced expiratory volumePrevalenceSmokersPulmonary disease, chronic obstructiveEosinophiliaRisk factorsResearch articleopen accessEnfermedad pulmonar obstructiva crónicaEosinofiliaEosinófilosFactores de riesgoFumadoresPrevalenciaVolumen espiratorio forzado10.1183/13993003.01162-20171399-3003https://erj.ersjournals.com/content/erj/50/5/1701162.full.pdf416330200016